Kidney and Neoplastic Disease: Overview with a Particular Interest to Interpretation of Cancer Biomarkers

Coppolino, Giuseppe; Simeoni, Mariadelina; Rivoli, Laura; Summaria, Chiara; Bolignano, Davide

doi:10.1007/978-94-007-7699-9_13

Biomarkers in Kidney Disease 2016

DOI: 10.1007/978-94-007-7699-9_13

|View full text |Cite

Kidney and Neoplastic Disease: Overview with a Particular Interest to Interpretation of Cancer Biomarkers

Giuseppe Coppolino¹,

Mariadelina Simeoni²,

Laura Rivoli³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2020

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

When ESKD complicates cancer screening and cancer treatment

Yasin

Holley

2020

Seminars in Dialysis

View full text Add to dashboard Cite

End-stage kidney disease (ESKD) affects the recommended screening, incidence, treatment, and mortality of cancer. Cancer occurring in a patient with ESKD can influence candidacy for kidney transplantation as well as dialysis decision-making and cancer treatment. Certain cancers are more common among ESKD patients, notably, viral-mediated cancers that are associated with human papilloma or hepatitis viruses, and urothelial cancers associated with analgesic and Balkan nephropathies. Solid tumors are not believed to occur more frequently in ESKD patients. The presence of ESKD may confer a higher risk of post-surgical complications as well as mortality. The cost-effectiveness of cancer screening depends upon individual cancer risk and estimated overall survival. The high mortality associated with ESKD argues against routine cancer screening in dialysis patients. Cancer treatment in ESKD may be complicated by the need to avoid, adjust doses of and/or coordinate the timing of administration of imaging contrast, chemotherapy, and immunotherapy with dialysis treatments. There is a general dearth of information on the treatment of cancer in ESKD patients. These issues will be discussed, and some general guidelines presented based upon the current literature.

show abstract

When ESKD complicates cancer screening and cancer treatment

Yasin

Holley

2020

Seminars in Dialysis

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Kidney and Neoplastic Disease: Overview with a Particular Interest to Interpretation of Cancer Biomarkers

Cited by 1 publication

References 58 publications

When ESKD complicates cancer screening and cancer treatment

When ESKD complicates cancer screening and cancer treatment

Contact Info

Product

Resources

About